ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma

Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomised Forte trial

Latest data for managing ALK NSCLC patients

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of the ITCC-059 study

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL

OncoAlert and ecancer weekly roundup for November 22 - Dec 5, 2020

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation

Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data

Five year update of ECHELON-1 for classical Hodgkin lymphoma

Real world management of multiple myeloma patients

Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study